CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD

Chengdu Kanghong Pharmaceutical Group Co., Ltd

002773

CNE1000020C4

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
22.71 ^CNY	+0.66%		-3.44%	+23.16%

Apr. 29	Kanghong Pharmaceutical's Unit Gets US FDA's Green Light to Test Macular Degeneration Drug	MT
Apr. 29	Kanghong Pharmaceutical's Unit Gets Nod to Trial Macular Degeneration Drug	MT

Chengdu Kanghong Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2023

April 24, 2024

Chengdu Kanghong Pharmaceutical Group Co. Ltd. proposed final cash dividend/10 shares (tax included) is CNY 3.8000000 for the year 2023.

Latest news about Chengdu Kanghong Pharmaceutical Group Co., Ltd

Kanghong Pharmaceutical's Unit Gets US FDA's Green Light to Test Macular Degeneration Drug	Apr. 29	MT
Kanghong Pharmaceutical's Unit Gets Nod to Trial Macular Degeneration Drug	Apr. 29	MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2023	Apr. 24	CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Kanghong Pharmaceutical's Mosapride Citrate Tablets Wins Centralized Procurement Bid	Apr. 17	MT
Kanghong Pharmaceutical's Beijing Unit Gets China's Approval for Clinical Trials for Anti-Tumor Injection	Mar. 06	MT
Kanghong Pharmaceutical's Unit Gets Nod to Trial Psoriasis Drug	Feb. 27	MT
Kanghong Pharmaceutical Gets Nod for Registration of Escitalopram Oxalate Tablets	Dec. 12	MT
Kanghong Pharma's Aripiprazole Oral Solution Chosen for China's Centralized Drug Procurement	Nov. 08	MT
Kanghong Pharma Gets FDA Nod to Trial Drug Against Fatty Liver Disease	Nov. 06	MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Kanghong Pharmaceutical Gets US FDA's Clinical Trial Nod for Antidepressant	23-10-24	MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-27	CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Executive Changes	23-08-04	CI
Kanghong Pharma Gets Nod to Trial Antidepressant	23-07-20	MT
Chengdu Hongji Biotechnology Co., Ltd. announced that it expects to receive CNY 159.736344 million in funding from Chengdu Kanghong Pharmaceutical Group Co., Ltd, Chengdu Kangji Enterprise Management Consulting Partnership (Limited Partnership), Chengdu Kangyin Enterprise Management Consulting Partnership (Limited Partnership), Chengdu Kangzhi Technology Consulting Partnership (Limited Partnership)	23-07-11	CI
Kanghong Pharma Gets Continued Protection for Traditional Chinese Medicine	23-06-20	MT
Chengdu Kanghong Pharmaceutical Group Co., Ltd Announces Final Cash Dividend on Share A for 2022, Payable on June 6, 2023	23-05-30	CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Approves Cash Dividend for the Year 2022	23-05-24	CI
Chengdu Kanghong Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Chengdu Kanghong Pharma Wins Orphan Drug Designation in US	23-02-16	MT
Kanghong Pharma’s Eye Drug Added to China’s Medical Insurance Catalog	23-01-20	MT
Kanghong Pharma Sees 121% Jump in 2022 Profit	23-01-19	MT
Kanghong Pharma Gets Marketing Nod in China for Antidepressant	22-12-23	MT

Chart Chengdu Kanghong Pharmaceutical Group Co., Ltd

Duration

Period

Chart Chengdu Kanghong Pharmaceutical Group Co., Ltd

More charts

Chengdu Kanghong Pharmaceutical Group Co., Ltd is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines, chemical drugs and biological products. The Companyâs main products include Conbercept Ophthalmic Injection, Songling capsules conducive to blood vessels, Keluoxin capsules, venlafaxine hydrochloride capsules and sustained release tablets, aripiprazole tablets and orally disintegrating tablets, mosapride citrate tablets and dispersible tablets, dexzopiclone tablets, Shuganjieyu capsules, Danshu capsules and Yiqing capsules, among others. The Company distributes its products in domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Chengdu Kanghong Pharmaceutical Group Co., Ltd

Trading Rating

Investor Rating

ESG Refinitiv

D-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.71

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD	+23.16%	2.87B
ELI LILLY AND COMPANY	+32.04%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.77%	371B
MERCK & CO., INC.	+20.01%	331B
ABBVIE INC.	+6.94%	290B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	209B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+7.99%	169B

Other Pharmaceuticals